Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von He Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Zhejiang Hospital, Zhejiang, Hangzhou, China. Hauptthemen laut MEDLINE: Chondrocytes, NF-E2-Related Factor 2, NF-kappa B, Osteoarthritis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Zhejiang Province Traditional Chinese Medicine Science and Technology Project.
Abstract (Originalsprache)
Osteoarthritis (OA) is a progressive joint disease characterized by extracellular matrix (ECM) degradation and inflammation, which is involved with pathological microenvironmental alterations induced by damaged chondrocytes. However, current therapies are not effective in alleviating the progression of OA. Isoquercetin is a natural flavonoid glycoside compound that has various pharmacological effects including anticancer, anti‐diabetes and blood lipid regulation. Previous evidence suggests that isoquercetin has anti‐inflammatory properties in various diseases, but its effect on OA has not been investigated yet. In this study, through western bolt, qRT‐PCR and ELISA, it was found that isoquercetin could reduce the increase of ADAMTS5, MMP13, COX‐2, iNOS and IL‐6 induced by IL‐1β, suggesting that isoquercetin could inhibit the inflammation and ECM degradation of chondrocytes. Through nuclear‐plasma separation technique, western blot and immunocytochemistry, it can be found that Nrf2 and NF‐κB pathways are activated in this process, and isoquercetin may rely on this process to play its protective role. In vivo, the results of X‐ray and SO staining show that intra‐articular injection of isoquercetin reduces the degradation of cartilage in the mouse OA model. In conclusion, the present work suggests that isoquercetin may benefit chondrocytes by regulating the Nrf2/NF‐κB signaling axis, which supports isoquercetin as a potential drug for the treatment of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Zhejiang Hospital, Zhejiang, Hangzhou, China.
- Department of Orthopedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
- Center for Drug Delivery System Research, School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.
ORCID-Profile: Jungao Zhu
Förderung
- Zhejiang Province Traditional Chinese Medicine Science and Technology Project
Zitieren
APA
Yu, H., Lou, J., Ni, L., Yan, M., Zhu, K., Mao, S., & Zhu, J. (2024). Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14620
Vancouver
Yu H, Lou J, Ni L, Yan M, Zhu K, Mao S, et al. Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14620
BibTeX
@article{Yu2024,
author = {Yu, He and Lou, Junsheng and Ni, Libin and Yan, Minwei and Zhu, Kewu and Mao, Su and Zhu, Jungao},
title = {Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14620}
}
EUVIMED